QQ客服 官方微博 反馈留言

	Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy A meta-analysis and clinical observation
	Yu, Dapeng; Zhang, Shuisheng; Feng, Alei; Xu, Deguo; Zhu, Qingshan; Mao, Yantao; Zhao, Yi; Lv, Yajuan; Han, Cuiping; Liu, Rujun
刊名	MEDICINE
	2019
卷号	98期号:19
关键词	clinical observation MAP meta-analysis osteosarcoma survival
DOI	10.1097/MD.0000000000015582
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4531927
专题	山东大学
作者单位	1.Shandong Prov Western Hosp, Dept Spine Surg, Jinan, Shandong, Peoples R China. 2.Peking Univ, Hosp 3, Dept Gen Surg,
推荐引用方式 GB/T 7714	Yu, Dapeng,Zhang, Shuisheng,Feng, Alei,et al. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy A meta-analysis and clinical observation[J]. MEDICINE,2019,98(19).
APA	Yu, Dapeng.,Zhang, Shuisheng.,Feng, Alei.,Xu, Deguo.,Zhu, Qingshan.,...&T 更多.(2019).Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy A meta-analysis and clinical observation.MEDICINE,98(19).
MLA	Yu, Dapeng,et al."Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy A meta-analysis and clinical observation".MEDICINE 98.19(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。